scholarly journals Regional and racial disparity in proximal gastric cancer survival outcomes 1996–2016: Results from SEER and China National Cancer Center database

2021 ◽  
Author(s):  
Lulu Zhao ◽  
Penghui Niu ◽  
Dongbing Zhao ◽  
Yingtai Chen
Keyword(s):  
Gastric Cancer ◽  
Racial Disparity ◽  
Cancer Survival ◽  
Cancer Center ◽  
Survival Outcomes ◽  
Proximal Gastric Cancer

Comprehensive Analysis of Breast Cancer Survival Outcomes in a Public Safety-Net Hospital Compared with an Adjacent Academic Cancer Center

2019 ◽  
Vol 229 (4) ◽  
pp. S146-S147
Author(s):  
Kristin N. Kelly ◽  
Emily Ryon ◽  
Francis Igor B. Macedo ◽  
Dido Franceschi ◽  
Mecker Moller ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Public Safety ◽  
Cancer Survival ◽  
Safety Net ◽  
Comprehensive Analysis ◽  
Breast Cancer Survival ◽  
Cancer Center ◽  
Survival Outcomes ◽  
Safety Net Hospital

Clinical outcomes of patients with gastric cancer according to pre and post-neoadjuvant chemotherapy PD-L1 immunohistochemistry (IHC) expression.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16569-e16569
Author(s):  
Heber Salvador de Castro Ribeiro ◽  
Wilson Luiz da Costa ◽  
Maria Dirlei de Souza Begnami ◽  
Celso Abdon Lopes Mello ◽  
Tatiane Neotti ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Gastric Cancer ◽  
Cox Regression ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Cancer Center ◽  
Survival Outcomes ◽  
Surgical Specimen ◽  
Locally Advanced Gastric Cancer

e16569 Background: The incidence, prognostic and predictive impacts of PD-L1 expression in locally advanced gastric cancer is unknown. We aimed to determine the expression of PD-L1 by CPS in the pre-treatment biopsy and surgical specimens of patients (pts) with gastric cancer who received neoadjuvant therapy and its association with pathological response and survival outcomes. Methods: Retrospective cohort of pts treated at a cancer center from 2007 to 2017. Pts with confirmed gastric or GEJ adenocarcinoma who received neoadjuvant treatment and curative-intent D2 surgery were included. Gastric stump tumors and those who had a total esophagectomy were excluded. Clinical data were obtained from medical charts. Biopsy samples and a tissue microarray with the most representative areas of the surgical specimen were used to detect PD-L1 IHC expression with 22C3 phamDx antibody. Results were analyzed using the CPS score. Overall and DFS survival included the Kaplan-Meier product-limit estimator in an ITT analysis and a Cox regression was used to obtain crude and adjusted HR for prognostic factors. Results: 270 pts were included: median age was 58.9 years, most (51.5%) had cT3-T4N+ stages, 45% had diffuse histology and 87.8% completed the preoperative regimen. 13% had a pCR, while 53% had minimal tumor regression. With a median follow-up of 60.3 months (CI 95% 54.7 – 65.8), the median OS and DFS were not reached. 11.4% of biopsies and 18.6% of surgical specimens had positive CPS, with a median score of 3 (IQR 2,0 – 7,5) and 9 (IQR 5.0 – 20.0) respectively. In 18.9% of paired samples the PD-L1 expression was found to be negative in the biopsy sample and positive in the surgical specimen. PD-L1 expression was neither associated with pathologic response after neoadjuvant chemotherapy, nor with survival outcomes. Conclusions: PD-L1 expression on the setting of locally advanced gastric cancer was low and it was different when biopsy and surgical specimens were compared. No impact on survival results could be detected. [Table: see text]

scholarly journals Multiple mediation analysis with survival outcomes: With an application to explore racial disparity in breast cancer survival

2018 ◽  
Vol 38 (3) ◽  
pp. 398-412 ◽  
Author(s):  
Qingzhao Yu ◽  
Xiaocheng Wu ◽  
Bin Li ◽  
Richard A. Scribner
Keyword(s):  
Breast Cancer ◽  
Mediation Analysis ◽  
Racial Disparity ◽  
Cancer Survival ◽  
Breast Cancer Survival ◽  
Survival Outcomes ◽  
Multiple Mediation ◽  
Multiple Mediation Analysis

Effect of clinical stage on survival outcome in patients with pathological stage I gastric cancer.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 178-178
Author(s):  
Masanori Tokunaga ◽  
Rie Makuuchi ◽  
Yuichiro Miki ◽  
Yutaka Tanizawa ◽  
Etsuro Bando ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Clinical Stage ◽  
Clinicopathological Characteristics ◽  
Survival Outcome ◽  
Nodal Status ◽  
Cancer Center ◽  
Survival Outcomes ◽  
Pathological Stage ◽  
Gastric Cancer Patients

178 Background: Patients with clinical stage (cStage) II or III gastric cancer are possible candidates for neoadjuvant chemotherapy. In this situation, contamination of pathological stage (pStage) I patients, for whom gastrectomy without adjuvant chemotherapy is a standard treatment of care, is a problem. However, it is unclear whether survival outcome in patients with cStage II-III / pStage I gastric cancer is as good as that of patients with cStage I / pStage I disease. The aim of the present study is to clarify the effect of clinical stage on survival outcome in patients with pStage I gastric cancer. Methods: The present study included 558 patients with pStage I gastric cancer who underwent gastrectomy between 2002 and 2006 at Shizuoka Cancer Center, Japan. Clinicopathological characteristics were investigated, and survival outcome was compared between cStage I and cStage II-III. In addition, we investigated the effect of other clinical factors, including clinically diagnosed tumor depth (cT) and nodal status (cN), on survival outcome. Results: The present retrospective cohort includs 368 male and 190 female patients, with median age of 64 years Five-year survival rate (5ysr) was significantly worse in cStage II-III (84.2%) than in cStage I (95.5%, p=0.003). 5ysr was also worse in cT2-4 (86.6%) than in cT1 (96.3%, p<0.001). On the contrary, clinical nodal status did not affect survival outcome of pStage I patients. Conclusions: cT and cStage affected survival outcomes of patients with pStage I gastric cancer. Patients who are preoperatively diagnosed with advanced disease have worse survival outcomes and can be candidates for neoadjuvant chemotherapy.

scholarly journals Effect of total number of harvested lymph nodes on survival outcomes after curative resection for gastric adenocarcinoma: findings from an eastern high-volume gastric cancer center

BMC Cancer ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Shiela S. Macalindong ◽  
Kwang Hee Kim ◽  
Byung-Ho Nam ◽  
Keun Won Ryu ◽  
Norihito Kubo ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lymph Nodes ◽  
Gastric Adenocarcinoma ◽  
Curative Resection ◽  
High Volume ◽  
Cancer Center ◽  
Survival Outcomes

scholarly journals Treatment Selection and Survival Outcomes in Locally Advanced Proximal Gastric Cancer: A National Cancer Data Base Analysis

2020 ◽  
Vol 10 ◽  
Author(s):  
Song Tang ◽  
Fangfang Liu ◽  
Yumin Li ◽  
Lulu Zhao ◽  
Xiang Wang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Data Base ◽  
Locally Advanced ◽  
National Cancer Data Base ◽  
Treatment Selection ◽  
Survival Outcomes ◽  
Proximal Gastric Cancer ◽  
Cancer Data ◽  
Base Analysis

scholarly journals Clinicopathological Characteristics, Survival Outcomes, and Genetic Alterations of Younger Patient With Gastric Cancer: Results From China National Cancer Center and cBioPortal

2021 ◽  
Author(s):  
Penghui Niu ◽  
Huang Huang ◽  
Lulu Zhao ◽  
Tongbo Wang ◽  
Xiaojie Zhang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Older Patients ◽  
Genetic Alterations ◽  
Clinicopathological Characteristics ◽  
Stage Iii ◽  
Cancer Center ◽  
Survival Outcomes ◽  
Younger Patients ◽  
Ptnm Stage ◽  
Tumor Stages

Abstract BackgroundSurvival outcomes of younger patients with gastric cancer (GC) remains controversial. The present study sought to explore clinicopathological characteristics, survival outcomes, and genetic alterations in the younger and older patients with GC.MethodsPatients with GC were identified from the China National Cancer Center Gastric Cancer Database (NCCGCDB) during 1998–2018. Survival analysis was conducted via Kaplan-Meier estimates and Cox proportional hazards models. Sequencing data were enrolled from the China National Cancer Center, TCGA, and MSKCC databases. ResultsA total of 1146 younger and 16988 older cases were included. Patients in the younger group were predominant in poor differentiation (53.7% versus 33.8%, P<0.0001), and pTNM stage IV (19.5% versus 11.8%, P<0.001). The 5-year overall survival (OS) of patients in NCCGCDB has noticeable increased from 1998 to 2018. Younger age was an independent prognostic factor for GC patients in pTNM stage III (P=0.014), while other stages showed no difference. Compared to the younger, older patients had a higher mutation frequency in LRP1B, GNAS, APC, KMT2D genes (all P< 0.05). In addition, although no significant difference, results of the China National Cancer Center, TCGA, and MSKCC cohorts indicated that younger patients dominated in CDH1, RHOA, and CTNNB1 mutations.ConclusionsStable proportion of younger cases and noticeable survival improvements were reported in the China National Cancer Center. Younger patients with pTNM stage III had a worse survival than older, while other tumor stages showed no difference. Furthermore, distinctive molecular characteristics were identified in younger GC patients, which might partly explain histopathological behaviors and prognosis of in this subpopulation.

scholarly journals Chemotherapy Delays Are Associated with Inferior Outcome in Acute Lymphoblastic Leukemia: A Retrospective Study from a Tertiary Cancer Center in South India

2021 ◽  
Vol 42 (01) ◽  
pp. 051-060
Author(s):  
Vineet Agrawal ◽  
Smita Kayal ◽  
Prasanth Ganesan ◽  
Biswajit Dubashi
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Univariate Analysis ◽  
Cancer Center ◽  
Survival Outcomes ◽  
Separate Analysis ◽  
Term Survival ◽  
Free Survival ◽  
Intensive Phase ◽  
The Impact

Abstract Background Treatment protocols for acute lymphoblastic leukemia (ALL) have evolved over time to give excellent cure rates in children and moderate outcomes in adults; however, little is known how delays in chemotherapy affect long-term survival. Objectives To find the association of delays during different treatment phases on the survival outcomes. Materials and Methods Data from 149 ALL cases treated between 2009 and 2015 were retrospectively analyzed. Treatment course in commonly used protocols was divided into three phases—induction, consolidation (postremission), maintenance, and also a combined intensive phase (induction plus consolidation) for the purpose of analysis, and delay in each phase was defined based on clinically acceptable breaks. Analysis was done to find the impact of treatment delay in each phase on the survival outcomes. Results The median age was 12 years (range, 1–57). Multi-center Protocol-841 (MCP-841) was used for 72%, German Multicenter Study Group for Adult ALL (GMALL) for 19%, and Berlin, Frankfurt, Muenster, 95 protocol (BFM-95) for 9% of patients. Delay in induction was seen in 52%, consolidation in 66%, and during maintenance in 42% of patients. The median follow-up was 41 months, and 3-year survival outcomes for the entire cohort were event-free survival (EFS)—60%, relapse-free survival (RFS)—72%, and overall survival (OS)—68%. On univariate analysis, delay in induction adversely affected EFS (hazard ratio [HR] = 1.78, p = 0.04), while delay in intensive phase had significantly worse EFS and RFS (HR = 2.41 [p = 0.03] and HR = 2.57 [p = 0.03], respectively). On separate analysis of MCP-841 cohort, delay in intensive phase affected both EFS (HR = 3.85, p = 0.02) and RFS (HR = 3.42, p = 0.04), whereas delay in consolidation significantly affected OS with (HR = 4.74, p = 0.04) independently. Conclusion Treatment delays mostly in intensive phase are associated with worse survival in ALL; attempts should be made to maintain protocol-defined treatment intensity while adequately managing toxicities.

scholarly journals No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Roman Rüdiger ◽  
Franziska Geiser ◽  
Manuel Ritter ◽  
Peter Brossart ◽  
Mignon-Denise Keyver-Paik ◽  
...  
Keyword(s):  
Treatment Response ◽  
Cancer Survival ◽  
Survival Rates ◽  
Migration Background ◽  
Comprehensive Cancer Center ◽  
Matched Pair ◽  
Cancer Center ◽  
German Population ◽  
Matched Pair Analysis ◽  
Immigrant Background

Abstract Background Immigration has taken the central stage in world politics, especially in the developed countries like Germany, where the continuous flow of immigrants has been well documented since 1960s. Strikingly, emerging data suggest that migrant patients have a poorer response to the treatment and lower survival rates in their new host country, raising concerns about health disparities. Herein, we present our investigation on the treatment response rate and cancer survival in German patients with and without an immigrant background that were treated at our comprehensive cancer center in Germany. Methods Initially, we considered 8162 cancer patients treated at the Center for Integrated Oncology (CIO), University Hospital Bonn, Germany (April 2002–December 2015) for matched-pair analysis. Subsequently, the German patients with a migration background and those from the native German population were manually identified and catalogued using a highly specific name-based algorithm. The clinical parameters such as demographic characteristics, tumor characteristics, defined staging criteria, and primary therapy were further adjusted. Using these stringent criteria, a total of 422 patients (n = 211, Germans with migration background; n = 211, native German population) were screened to compare for the treatment response and survival rates (i.e., 5-year overall survival, progression-free survival, and time to progression). Results Compared to the cohort with migration background, the cohort without migration background was slightly older (54.9 vs. 57.9 years) while having the same sex distribution (54.5% vs. 55.0% female) and longer follow-up time (36.9 vs. 42.6 months). We did not find significant differences in cancer survival (5-year overall survival, P = 0.771) and the response rates (Overall Remission Rate; McNemar’s test, P = 0.346) between both collectives. Conclusion Contrary to prior reports, we found no significant differences in cancer survival between German patients with immigrant background and native German patients. Nevertheless, the advanced treatment protocols implemented at our comprehensive cancer center may possibly account for the low variance in outcome. To conduct similar studies with a broader perspective, we propose that certain risk factors (country-of-origin-specific infections, dietary habits, epigenetics for chronic diseases etc.) should be considered, specially in the future studies that will recruit new arrivals from the 2015 German refugee crisis.

Sign in / Sign up

Export Citation Format

Share Document